参考文献
[1]KOK J B, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors[J]. Cancer Res, 2002.
[2]TINAL M, et al.DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer[J]. Eur Urol, 2004.
[3]KLECKA J, et al. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis [J]. Anticancer Res, 2010.
[4]NEVES A F, et al.Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis[J]. Clinical Biochem, 2008.
[5]LANDERS K A, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer[J]. Int J Cancer, 2005.
[6]MEARINI E, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer[J]. Biomarkers, 2009.
[7]CAO DL, et al. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer[J]. Prostate, 2011.
[8]SALAMI S S, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer[J]. Urol Onco, 2011,
[9]FAN J K, et al. Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene[J]. Int J Cancer, 2010.
[10]BUSSEMAKERS M J, et al. a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer Res, 1999.
[11]HESSELS D, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer[J]. Eur Urol, 2003.
[12]V SRIKANTAN, et al. “PCGEMl, aprostatespecific gene, is overexpressed in prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, 2000.
[13]X Fu, et al. “Regulation of apoptosis by a prostate-specific and prostate cancer- associated noncoding gene, PCGEMl” [J]. DNA and Cell Biology, 2006.
[14]G PETROVICS, et al. “Elevated expression of PCGEMI, a prostate-specific gene with cell growthpromoting function, is associated with high-risk prostate cancer patients” [J]. Oncogene, 2004.
[15]L YANG, et al. “LncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs” [J]. Nature, 2013.
[16]Fu X, et al. Regulation of apoptosis by a prostate-specific and prostate cancer- associated noncoding gene, PCGEMI[J]. DNA Cell Biol, 2006.
[17]PETROVICS G, et al.Elevated expression of PCGEMI, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients[J]. Oncogene, 2004.
[18]YANG L. et al.1ncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs[J]. Nature, 2013.
[19]JOHN R. et al. The 1ncRNAs PCGEMI and PRNCRl are not implicated in castration resistant prostate cancer[J]. Oncotarget, 2014.
[20]AHMADIYEH N, et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific longrange interaction with MYC[J]. Proc Natl Acad Sci U S A, 2010.
[21]AL OLAMA A A, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility[J]. Nat Genet, 2009.
[22]BEROUKHIM R, et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010.
[23]GUDMUNDSSON J, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24[J]. Nat Genet, 2007.
[24]SOTELO J, et al. Long-range enhancers on 8q24 regulate c-Myc[J]. Proc Natl Acad Sci U S A, 2010.
[25]TAYLOR B S, et al. Integrative genomic profiling of human prostate cancer[J]. Cancer Cell, 2010.
[26]JOHN R, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer[J]. Cancer Res, 2014.
[27]Ting-Hua Yan, et al. Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma[J]. Int J Clip Exp Pathol, 2015.
[28]GE X, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer[J]. Med Onco, 2009.
[29]JOHN R. et al. The Long Non-Coding RNAPCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc[J]. Neoplasia, 2014.
[30]FRANCESCO CREA, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer[J]. Oncotarget, 2012.
[31]R MALIK, et al. The 1ncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer [J]. Molecular Cancer Research, 2014.
[32]JI P, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lungcancer[J]. Oncogene, 2003.
[33]LAI M C, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J]. Med Oncol, 2011.
[34]TANO K, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes[J]. FEBS Lett, 2010.
[35]YAMADA K, et al. Phenotypic characterization of endometrial stromal sarcoma of the uterus[J]. Cancer Sci, 2006.
[36]XU C, et al. MALAT-1: a long non-coding RNA and its important end functional motif in colorectal cancer metastasis[J]. Int J Oncol, 2011.
[37]REN S C, et al. long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistent prostate cancer[J]. the journal of urology, 2013 (9).
[38]WANG F B, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer[J]. Oncotarget, 2011.
[39]HOLDCRAFT R W, et al. Androgen receptor function is required in Sertoli cells for the terminal differentiation of haploid spermatids[J]. Development, 2004.
[40]ROY A K, et al. Regulation of androgen action[J]. Vitam Horm, 1999.
[41]TRAPMAN J, et al. Cloning, structure and expression of a cDNA encoding the human androgen receptor[J]. Biochem Biophycs Res Commun, 1988.
[42]YONG E L, et al. Androgen receptor transactivation domain and control of spermatogenesis [J]. Rev Reprod, 1998.
[43]SIMENTAL J A, et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor[J]. J Biol Chem, 1991.
[44]JENSTER G, et al. Domains of the human and rogenreceptor involved in steroid binding, transcriptional activation, and subcellular localization[J]. Mol Endocrinol, 1991.
[45]JENSTER G, et al. Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites[J]. Biochemistry, 1994.
[46]JENSTER G, et al. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor[J]. J Biol Chem, 1995.
[47]CHAMBERLAIN N L, et al. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain[J]. J Biol Chem, 1996.
[48]GAO T, et al. Transcriptional activation and transient expression of the human androgen receptor[J]. J Steroid Biochem Mol Biol, 1996.
[49]REID J, et al. Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions[J]. J Biol Chem, 2002.
[50]MCEWAN I J. Structural and functional alterations in the androgen receptor in spinal bulbar muscular atrophycs[J]. Biochem Soc Trans, 2001.
[51]IRVINE R A, et al. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length[J]. Hum Mol Genet, 2000.
[52]SHAFFER P L, et al. Structural basis of androgen receptor binding to selective androgen response elements[J]. Proc Natl Acad Sci U S A, 2004.
[53]KUMAR R, et al. The structure of the nuclear hormone receptors[J]. Steroids, 1999.
[54]YLIKOMI T, et al. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors[J]. EMBO J, 1992.
[55]KAKU N, et al. Characterization of nuclear import of the domain-specific and rogen receptor in association with the importin alpha/beta and Ran-guanosine 5’-triphosphate systems[J]. Endocrinology, 2008.
[56]HE B, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance[J]. Mol Cell, 2004.
[57]POUJOL N, et al. Specific recognition of androgens by their nuclear receptor. A structure-function study[J]. J Biol Chem, 2000.
[58]MATIAS P M, et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations[J]. Biol Chem, 2000.
[59]SAPORITA A J, et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor[J]. J Biol Chem, 2003.
[60]DEBES J D, et al. The role of androgens and the androgen receptor in prostate cancer[J]. Cancer Lett, 2002.
[61]HEINLEIN C A, et al. Androgen receptor in prostate cancer. Endocr Rev 2004.
[62]KNUDSEN K E, et al. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer[J]. Trends Endocrinol Metab, 2010.
[63]YUAN X, et al. Mechanisms mediating androgen receptor reactivation after castration[J]. Urol Oncol, 2009.
[64]WALTERING K K, et al. Androgen receptor (AR) aberrations in castration-resistant prostate cancer[J]. Mol Cell Endocrinol, 2012.
[65]LATTOUF J B, et al. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy[J]. Nat Clin Pract Urol, 2006.
[66]REN S, et al.RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings[J]. Cell Research, 2012.
[67]K TAKAYAMA, et al. Androgenresponsive long noncoding RNA CTBP1-AS promotes prostate cancer[J]. EMBO Journal, 2013.
[68]CUI Z, et al. The prostate cancer-up-regulated long noncoding RNA P1ncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor[J]. Urologic Oncology: Seminars and Original Investigations, 2013.
[69]WANG G, et al.Zbtb7asuppressesprostate through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion[J]. “ Nature Genetics, 2013.